RT Journal Article
SR Electronic
T1 Symptoms persisting after hospitalization for COVID-19: 12 months interim results of the COFLOW study
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.11.21267652
DO 10.1101/2021.12.11.21267652
A1 Bek, L.M.
A1 Berentschot, J.C.
A1 Heijenbrok-Kal, M.H.
A1 Huijts, S.
A1 van Genderen, M.E.
A1 Vlake, J.H.
A1 van Bommel, J.
A1 Aerts, J.G.J.V.
A1 Ribbers, G.M.
A1 van den Berg-Emons, H.J.G.
A1 Hellemons, M.E.
A1 ,
YR 2021
UL http://medrxiv.org/content/early/2021/12/13/2021.12.11.21267652.abstract
AB Introduction A large proportion of patients experiences a wide range of sequelae after acute COVID-19 infection, especially after severe illness. The long-term health sequelae need to be assessed. Our objective was to longitudinally assess persistence of symptoms and clusters of symptoms up to 12 months after hospitalization for COVID-19, and to assess determinants of the main persistent symptoms.Methods In this multicenter prospective cohort study patients with COVID-19 are followed up for 2 years with measurements at 3, 6, 12, and 24 months after hospital discharge. Here, we present interim results regarding persistent symptoms up to 12 months. Symptoms were clustered into physical, respiratory, cognitive and fatigue symptoms.Results We included 492 patients; mean age was 60.2±10.7 years, 335 (68.1%) males, median length of hospital stay 11 (6.0-27.0) days. At 3 months after discharge 97.0% of the patients had at least 1 persisting symptom, this declined to 95.5% and 92.0% at 6 and 12 months, respectively (p=0.010). Muscle weakness, exertional dyspnea, fatigue, and memory and concentration problems were the most prevalent symptoms with rates over 50% during follow-up. Over time, muscle weakness, hair loss, and exertional dyspnea decreased significantly (p<0.001), while other symptoms, such as fatigue, concentration and memory problems, anosmia, and ageusia persisted. Symptoms from the physical and respiratory cluster declined significantly over time, in contrast to symptoms from the fatigue and cognitive clusters. Female gender was the most important predictor of persistent symptoms and co-occurrence of symptoms from all clusters. Shorter hospital stay and treatment with steroids were related with decreased muscle weakness; comorbidity and being employed were related with increased fatigue; and shorter hospital stay and comorbidity were related with memory problems.Conclusion The majority of patients experienced COVID-19 sequelae up to 12 months after hospitalization. Whereas physical and respiratory symptoms showed slow gradual decline, fatigue and cognitive symptoms did not evidently resolve over time. This finding stresses the importance of finding the underlying causes and effective treatments for post-COVID condition, beside adequate COVID-19 prevention.Competing Interest StatementDr. Aerts reports personal fees and non-financial support from msd, personal fees from bms, personal fees from boehringer ingelheim, personal fees from amphera, personal fees from eli-lilly, personal fees from takeda, personal fees from bayer, personal fees from roche, personal fees from astra zeneca, outside the submitted work; In addition, Dr. Aerts has a patent allogenic tumor cell lysate licensed to amphera, a patent combination immunotherapy in cancer pending, and a patent biomarker for immunotherapy pending. Other authors have nothing to disclose.Clinical Protocols https://pubmed.ncbi.nlm.nih.gov/34419032/ Funding StatementThe study is funded by the COVID-19 Program Care and Prevention of The Netherlands Organization for Health Research and Development (ZonMw, grant number 10430022010026), and Rijndam Rehabilitation and Laurens (both in Rotterdam, The Netherlands). The review committee COVID-19 of the funding body has independently reviewed the study protocol. None of the funders have a role in the study design, nor are involved in analysis and interpretation of data or writing of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Medical Ethics Committee of the Erasmus Medical Center (MC) approved this study (MEC-2020-0487).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors